Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | TYMP | P19971 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8855534 | 1.00 | KMT2A (0.67) | KMT2ALMNATHRBCYP2C19L3MBTL1 | |
| SCHEMBL8895819 | 1.00 | KMT2A (0.67) | KMT2ALMNATHRBCYP2C19L3MBTL1 | |
| SCHEMBL11352268 | 0.94 | KMT2A (0.64) | KMT2ALMNATHRBCYP2C19L3MBTL1 | |
| SCHEMBL11379553 | 0.94 | KMT2A (0.64) | KMT2ALMNATHRBCYP2C19L3MBTL1 | |
| Hydrochloric Acid SCHEMBL11376105 | 0.93 | KMT2A (0.63) | KMT2ALMNATHRBCYP2C19L3MBTL1 | |
| Pimonidazole SCHEMBL51977 | 0.93 | KMT2A (0.63) | KMT2ALMNATHRBCYP2C19L3MBTL1 | |
| Hydrochloric Acid SCHEMBL11379185 | 0.92 | KMT2A (0.62) | KMT2ALMNATHRBCYP2C19L3MBTL1 | |
| Pimonidazole SCHEMBL11390660 | 0.92 | KMT2A (0.62) | KMT2ALMNATHRBCYP2C19L3MBTL1 | |
| SCHEMBL12396375 | 0.91 | KMT2A (0.78) | KMT2ALMNATHRBCYP2C19CA12 | |
| SCHEMBL11350180 | 0.91 | KMT2A (0.60) | KMT2ALMNATHRBCYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | claimed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | claimed |
| EP-1951213-B1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | MORVUS TECHNOLOGY LTD (GB) | 2012-11-14 | — | — | EP | claimed |
| US-20100104515-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | GORDIAN PHARMA LIMITED (GB) | 2010-04-29 | — | — | US | claimed |
| CN-1582166-A | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-02-16 | — | — | CN | claimed |
| US-12617858-B2 | Anti-Müllerian hormone receptor 2 antibodies and methods of use | THE CLEVELAND CLINIC FOUNDATION (US) | 2026-05-05 | — | — | US | disclosed |
| EP-3226909-B1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12583865-B2 | Biologically active taxane analogs and methods of treatment by oral administration | TAPESTRY PHARMACEUTICALS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260060943-A1 | OVARIAN CANCER VACCINES | CLEVELAND CLINIC FOUND (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260041712-A1 | VACCINE ADJUVANTS AND FORMULATIONS | CLEVELAND CLINIC FOUND (US) | 2026-02-12 | — | — | US | disclosed |
| US-12472205-B2 | Vaccine adjuvants and formulations | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-11-18 | — | — | US | disclosed |
| US-12357593-B2 | Ovarian cancer vaccines | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-07-15 | — | — | US | disclosed |
| CN-1582166-A | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-02-16 | — | — | CN | disclosed |
| US-5659048-A | CHEMOSENSITIZER, RADIOSENSITIZER ADMINISTERING TO PATIENTS WHOM ARE SENSITIVE TO RADIATION OR CHEMOTHERAPY | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1997-08-19 | — | — | US | disclosed |
| US-5652255-A | ADMINISTERING NITROIMIDAZOLE DERIVATIVE NITRIC OXIDE SYNTHASE INHIBITOR; ANTITUMOR AGENTS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1997-07-29 | — | — | US | disclosed |
| US-5543527-A | ANTITUMOR AGENTS | BRITISH TECHNOLOYG GROUP LIMITED (GB) | 1996-08-06 | — | — | US | disclosed |
| US-5481000-A | RADIOSENSITIZERS OR CHEMOSENSITIZERS; PATENT CLAIMS CHIRAL 3-/2-HYDROXY-3-/2-NITROIMIDAZOL-1-YL/PROPYL/-2-OXAZOLIDINONE, HAVING /S/ CONFIGURATION AT OH CARBON AND FREE OF /R/ CONFIGURATION | WARNER-LAMBERT COMPANY (US) | 1996-01-02 | — | — | US | disclosed |
| EP-0652870-A1 | Process for preparing chiral (((2-bromoethyl)amino)methyl)-2-nitro-1H-imidazol-1- ethanol and related compounds | WARNER-LAMBERT COMPANY (US) | 1995-05-17 | — | — | EP | disclosed |
| US-5342959-A | Process for preparing chiral [[(2-bromoethyl)-amino]methyl]-2-nitro-1H-imidazol-1-ethanol and related compounds | WARNER-LAMBERT COMPANY (US) | 1994-08-30 | — | — | US | disclosed |
| WO-1994015922-A1 | NOVEL PROCESS FOR PREPARING CHIRAL [[(2-BROMOETHYL)AMINO]METHYL]-2-NITRO-1H-IMIDAZOL-1-ETHANOL AND RELATED COMPOUNDS | WARNER LAMBERT COMPANY (US) | 1994-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104515-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | DERA, HOGA1, ALDOA | KMT2A 3827/4885LMNA 763/4885THRB 3904/4885 |
| US-20260060943-A1 | OVARIAN CANCER VACCINES | FSHR, GNRHR, LHCGR | KMT2A 1250/4885LMNA 3921/4885THRB 234/4885 |
| US-12583865-B2 | Biologically active taxane analogs and methods of treatment by oral administration | TOP2A, TOP1, TOP2B | KMT2A 1588/4885LMNA 4130/4885THRB 1017/4885 |
| US-20260041712-A1 | VACCINE ADJUVANTS AND FORMULATIONS | LITAF, CHI3L2, S100B | KMT2A 3850/4885LMNA 2126/4885THRB 1205/4885 |
| US-12617858-B2 | Anti-Müllerian hormone receptor 2 antibodies and methods of use | TGFBR2, TNFSF11, TNFRSF9 | KMT2A 602/4885LMNA 1313/4885THRB 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.